日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery

用靶向PD-L1的融合蛋白改造的实体瘤CAR-T细胞,用于局部递送IL-12

Murad, John P; Christian, Lea; Rosa, Reginaldo; Ren, Yuwei; Buckley, Alyssa J; Lee, Eric Hee Jun; Lopez, Lupita S; Park, Anthony K; Yang, Jason; Yamaguchi, Yukiko; Trac, Candi; Adkins, Lauren N; Chang, Wen-Chung; Martinez, Catalina; June, Carl H; Forman, Stephen J; Ishihara, Jun; Lee, John K; Stern, Lawrence A; Priceman, Saul J

Tumor PD-L1 induces β2m ubiquitylation and degradation for cancer cell immune evasion.

肿瘤PD-L1诱导β2m泛素化和降解,从而使癌细胞逃避免疫攻击。

Zhao Qiuling, Li Chenglong, Zhang Mengsi, Gao Tingfang, Wang Zhidong, Li Zhi, Qin Yan, Xue Xinwen, Chen Mengyun, Xu Chengping, Zhang Guozhi, Cui Xiang, Zhang Kangjian, Qi Xiaowei, Bian Xiu-Wu, Yang Yi

First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expression

一线治疗方案:替雷利珠单抗联合贝伐珠单抗和CAPOX方案,用于治疗程序性死亡配体1(PD-L1)表达低的转移性胃食管腺癌

Jia, Ru; Wang, Yan-Rong; Liu, Fang-Fang; Ma, Yue; Si, Hai-Yan; Han, Lu; Gou, Miao-Miao; Tan, Zhao-Li; Zhang, Nan; Deng, Guo-Chao; Fan, Meng-Jiao; Shi, Yue; Zhang, Yao-Yue; Jia, Yu-Shan; Xu, Jun-Nan; Su, Xiao-Xing; Han, Quan-Li; Wang, Zhi-Kuan; Dai, Guang-Hai

Inhalable PD-L1-engineered hybrid cellular vesicles suppress excessive neutrophil activation and restore mitochondrial homeostasis to alleviate ischemia-reperfusion lung injury and pneumonia.

可吸入的 PD-L1 工程化混合细胞囊泡可抑制中性粒细胞过度活化,恢复线粒体稳态,从而减轻缺血再灌注肺损伤和肺炎。

Yuan Haoxiang, Wang Wei, Ma Jian, Li Huafu, Reis Rui Luís, Chen Ying, Xu Xin, Yuan Yingying, Li Yiwen, Yan Leping, Fan Zhijin, Liao Yuhui, He Jianxing

Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents

国家癌症研究所开展的包含PD-1或PD-L1抑制剂的试验中,免疫检查点抑制剂诱发糖尿病的情况

Quandt, Zoe E; Finnigan, Shanda; Hill, Vanessa; Dib, Joe E; Burian, Jason; Tessler, Sapir; Davidson, Darah; Naqash, Abdul Rafeh; Anderson, Mark S; Othus, Megan; Sharon, Elad

Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma

抗PD-1/PD-L1、VEGF和CTLA-4阻断对肿瘤免疫微环境的独特调节,为肝细胞癌的三联疗法提供了理论依据。

Iwamoto, Hideki; Koga, Hironori; Kawaguchi, Takumi

Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response.

靶向 STING、TGF-β 和 PD-L1 的三重靶向作用可增强 CXCL16-CXCR6 信号传导,从而产生强大的抗肿瘤反应。

Yi Ming, Li Tianye, Gu Yinhui, Niu Mengke, Xue Dixuan, Hu Shengtao, Wu Yuze, Zhao Bin, Zhang Di, Ma Yingkang, Zhang Minjun, Zhang Jing, Yan Yongxiang, Zhou Pengfei, Zhang Xiaojun, Zhou Zhuxian, Chu Qian, Wu Kongming, Dai Zhijun

TRIM11 potentiates antitumor immunity via inhibition of the IFN-γ/PD-L1 axis.

TRIM11 通过抑制 IFN-γ/PD-L1 轴增强抗肿瘤免疫力。

Xu Yingying, Cai Runjie, Liu Maoxuan, Fan Xiaokai, Wan Xiaochun, Yang Xiaolu, Bi Jiacheng, Chen Liang

Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer

对已发表的用于检测非小细胞肺癌中PD-L1状态的CT模型进行独立测试

O'Shea, Robert; Horst, Carolyn; Manickavasagar, Thubeena; Josephides, Eleni; Hunter, Sarah; Taniere, Phillipe; Nonaka, Daisuke; Van Hemelrijck, Mieke; Spicer, James; Hughes, Daniel J; Cook, Gary J R; Bille, Andrea; Karapanagiotou, Eleni; Goh, Vicky

Expansion of bone marrow adipocytes in obese mice leads to PD-L1-driven bone marrow immunosuppression and osteoclastogenesis.

肥胖小鼠骨髓脂肪细胞的扩增导致 PD-L1 驱动的骨髓免疫抑制和破骨细胞生成。

Costa Samantha N, Chlebek Carolyn, Gray Lindsey, Caradonna Peter, Ryzhov Sergey, Rosen Clifford J